September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
How to Slow CKD Progression: Treatment Essentials for Primary Care
Most patients with chronic kidney disease are treated in primary care where the primary goal is twofold: slow progression and prevent complications. Find essentials of both, here.
SURPASS-4: Tirzepatide Reduces A1c, Weight vs Glargine in Patients with T2D, High CV Risk
New topline data from the global SURPASS-4 trial shows treatment with investigational agent tirzepatide led to superior reductions in A1c and body weight vs insulin glargine.
ACC.21: Finerenone Shows Potential to Delay Afib Onset in Patients with CKD, T2D
ACC.2021: A new analysis of FIDELIO-DKD found patients with chronic kidney disease and type 2 diabetes were about 30% less likely to develop atrial fibrillation vs those treated with placebo.
VIDEO: Keep NASH on the Tip of your Diagnostic Tongue
VIDEO: Given the increasing morbidity and mortality associated with fatty liver disease in the US, it should be on the "tip of [your] diagnostic tongue," says Seth Baum, MD. He explains why.
ACC.21: Prediabetes Significantly Increases Risk for MACE, According to New Findings
ACC.21: Findings from a study released in advance of the ACC annual meeting suggest that prediabetes confers nearly twice the risk of major cardiovascular events vs normoglycemia.
T2D Complications Associated with Objective Measure of Poor Medication Adherence
Robust analyses of urine metabolites detects poor adherence with prescribed treatment in T2D and is associated with prevalence of micro- and macrovascular complications.
Diabetes Management in CKD: 10 Top Takeaways from KDIGO 2020
The 2020 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline integrates new treatments and practices with existing management strategies for CKD patients with diabetes.
FDA Approves Dapagliflozin to Treat Chronic Kidney Disease in Adults at Risk of Progression, Regardless of Diabetes Status
Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.
ACP: Clyde Yancy, MD, MSc Reviews Advances in Heart Failure Research and Treatment
ACP: Clyde W Yancy, MD, gave a comprehensive update on a year's worth of pivotal science in treatment of heart failure. Here are the highlights.
Early Intervention in Weight Management: Treating Pre-Obesity
Research shows that increased risk of chronic disease and mortality begins below a BMI classified as obesity. The earlier we intervene with at-risk patients, the greater the chance for success.
Bariatric Surgery Associated with Reduced Mortality in Patient with T2D, Obesity
Authors of a new study say their findings suggest bariatric surgery should be considered first-line treatment for the management of obesity in patients with type 2 diabetes.
Study: GLP-1 Receptor Agonist Therapy Reduces Asthma Exacerbations in Adults with Asthma, T2D
New findings suggest that patients with asthma and type 2 diabetes who use GLP-1 RAs for diabetes treatment intensification have fewer asthma exacerbations compared to other diabetes drugs.
A Weight-centric Approach to Obesity with T2D: How Pharmacotherapy Works
For frontline clinicians who care daily for patients with obesity and type 2 diabetes, a weight-centric approach to T2D, including antiobesity drugs, could help improve outcomes.
Functional Assessment Strengthens Red Meat-Heart Disease Association
Measures of heart function and anatomy were used to assess the effects of red and processed meat on cardiovascular health; findings were reported at ESC Preventive Cardiology 2021.
NAFLD & NASH in Primary Care: Facts, Definitions, & Figures in Brief
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis is increasing and early detection is critical. Brush up on basics with our slides.
Lifestyle Counseling in Primary Care Setting May Reduce Incidence of T2D in High-risk Patients
A recent study showed lifestyle counseling in primary care was effective in preventing type 2 diabetes in long-term follow-up.
Diabetes in Patients with CAD Independently Associated with Mortality, CV Events
In individuals with chronic coronary disease, the presence of diabetes increased the rate of death by 38% during a 5-year follow-up period in analysis of a worldwide patient registry.
SGLT2 Inhibitor Therapy May Reduce Risk of Atrial Arrhythmias in T2D
A recent meta-analysis suggests some sodium glucose cotransporter-2 inhibitor agents may protect against atrial and ventricular arrhythmias as well as sudden cardiac death in type 2 diabetes patients.
Dapagliflozin Found Effective for HFrEF in Men and Women
In a subanalysis of the landmark DAPA-HF trial, dapagliflozin benefits were observed in both men and women, an important finding given variable response to cardiovascular drugs among women.
Hyperglycemia in Hospitalized COVID-19 Patients Linked with Worse Outcomes
COVID-19 patients with hyperglycemia on hospital admission, with and without diabetes, had increased odds of intubation, ICU admission, and mortality, according to research presented at ENDO 2021.
Novel Once-weekly Insulin as Effective as Once-daily in Type 2 Diabetes with Less Hypoglycemia, Weight Gain
ENDO 2021: An investigational once-weekly insulin formulation was found as effective as daily basal insulin injection for glucose control with lower rates of hypoglycemia and less weight gain.
Semaglutide 2.4 mg Reduces Visceral Adiposity, Improves Lean Body Mass-to-Fat Mass Ratio
ENDO 2021: Obese individuals treated with semaglutide 2.4 mg vs placebo demonstrated improvements in body composition paralleling weight loss that may reduce risk for cardiometabolic disease.
Chronic Diseases in Multimorbidity May Share Origins, Study Finds
Using metabolomic profiling from more than 11 000 individuals, researchers identified common pathways linking seemingly unrelated diseases that often co-occur.
Eli Lilly’s Tirzepatide Significantly Reduced A1c, Body Weight in Adults with T2D
Results from a head-to-head study show the investigational medication, tirzepatide, led to superior A1c and body weight reductions compared to semaglutide.
Obesity Linked to Over Half of New Type 2 Diabetes Cases in US Annually
New research suggests obesity is responsible for 30%-53% of new type 2 diabetes cases in the US annually.
A1c Variability Predicts CVD in Type 2 Diabetes, Hypoglycemia May Mediate Impact
Variability in A1c during the first 2 years after T2D diagnosis is a strong predictor of CV disease; study authors note the risk may be mediated by severe hypoglycemic episodes.
George Bakris, MD: Heart Failure, Renal Disease, CV Risk Research is on Fire
Video: George Bakris, MD says over the next 3 years there is going to be an "explosion" in the number of studies we see in heart failure, diabetic kidney disease, and CV risk in general.
Brigham & Women's Diabetes Expert Highlights 2020 Research
Director of the Brigham and Women's Diabetes Program Marie McDonnell, MD, talked with our editor about 2020 studies on SGLT-2 inhibitors, insulin icodec, and more.
Study: Metabolic Surgery May be Cure for Type 2 Diabetes
Compared to medication and lifestyle changes, metabolic surgery is more effective in the long-term control of severe T2D, a new study found.
Exercise Insufficient to Overcome CVD Risks of Overweight/Obesity
Physical activity cannot compensate adequately for the negative impact of excess body weight on cardiometabolic health.